Johnson & Johnson (NYSE:JNJ) Shares Acquired by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 34.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 83,994 shares of the company’s stock after acquiring an additional 21,698 shares during the period. Johnson & Johnson makes up about 0.8% of Gladstone Institutional Advisory LLC’s portfolio, making the stock its 18th largest holding. Gladstone Institutional Advisory LLC’s holdings in Johnson & Johnson were worth $13,019,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atlantic Private Wealth LLC purchased a new stake in Johnson & Johnson during the 1st quarter worth approximately $32,000. GW&K Investment Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at $35,000. Dark Forest Capital Management LP boosted its stake in Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares during the last quarter. Ruedi Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $42,000. Finally, Kepos Capital LP acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several research reports. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Thursday, August 31st. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $170.65.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $160.56 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a market cap of $417.29 billion, a P/E ratio of 32.50, a P/E/G ratio of 3.47 and a beta of 0.54. The firm’s 50 day moving average price is $166.11 and its 200-day moving average price is $161.50. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the firm earned $2.59 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.